A	B	C
1	Main
2		Brand Name	Recentin, fka AZD-2171
3		Generic Name	cedarinib
4		Mechanism	VEGF1R, 2R and 3R inhibitor, PDGFr, Kit.
5			Subnanomolar potent at VEGFR-2 (<1nmol IC50), 5nm at VEGFR-1 and 3nm at VEGFR-3.
6		Administration	Oral qd
7		Indication	NSCLC, mCRC, RCC, GBM, AML/MDS, mHRPC, mOC, mHCC
8		Clinical Trials
9			Phase III "REGAL" in GBM
10
11			Phase III 1L mNSCLC Paclitaxel+Carboplatin+-Recentin n=750 - NCI sponsored.
12
13			Phase III 1L mCRC Recentin+FOLFOX/XELOX vs Placebo+FOLFOX/XELOX n=1050 - Began October 2006
14			Ethical issues (Avastin)? Met PFS but no improvement in OS. May 28 2010.
15
16			Phase II/II 1L mCRC Recentin+FOLFOX vs Avastin+FOLFOX n=1600 - Began August 2006
17			Did not meet primary endpoint (PFS).
18
19			Phase II 2L mCRC Recentin+FOLFOX vs Avastin+FOLFOX n=210
20
21			Phase II mNSCLC Gemcitabine+Cisplatin+-Recentin
22
23			Phase II mRCC
24			n=27 received monotherapy. 33% RR, 66.7% SD.
25
26			Phase II monotherapy in recurrent glioblastoma
27			n=31 treated, 8 were alive and progression-free at 6 months.
28			Median PFS of 111 days.
29
30
31			Phase I in patients with advanced solid tumors - JCO 2007
32			Part A: n=36 with solid tumors and liver mets.
33			Part B: n=47 with or without liver mets.
34			45mg/d was well-tolerated. Dose-related events included hypertension, diarrhea and dysphonia.
35			2 PRs, 22 patients with SD, dose-related tumor effect seen.